Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine
June 08 2023 - 12:20AM
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the
“Company” or “Burning Rock”) is pleased to announce that our
flagship comprehensive genomic profiling (CGP) product,
OncoScreenTM Plus, was featured in a phase 3 multi-regional
clinical trial (MRCT), along with FoundationOneCDx, in support of
advancement in breast cancer treatment.
The study, CAPItello-291, sponsored by our pharma client
AstraZeneca, is a phase 3 trial that assessed the efficacy and
safety of Capivasertib–fulvestrant therapy in advanced breast
cancer patients with hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative (HER2-) cancer whose
disease had progressed during or after aromatase inhibitor therapy.
The study demonstrated that Capivasertib–fulvestrant combination
therapy resulted in significantly longer progression-free survival
than treatment with fulvestrant alone.
In the study, Burning Rock's flagship comprehensive genomic
profiling (CGP) product, OncoScreenTM Plus, was used to determine
activating mutations in PIK3CA and AKT1 and inactivating
alterations in PTEN genes for patients enrolled in China. We are
proud to have supported our pharma client in such a high impact
study, after a rigorous test solution provider evaluation
process.
Reference[1] Capivasertib in Hormone
Receptor–Positive Advanced Breast Cancer. N ENGL J MED 388. June,
2023https://www.nejm.org/doi/full/10.1056/NEJMoa2214131
About Burning RockBurning Rock Biotech Limited
(NASDAQ: BNR and LSE: BNR), whose mission is to guard life via
science, focuses on the application of next generation sequencing
(NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage
cancer patients, and ii) cancer early detection, which has moved
beyond proof-of-concept R&D into the clinical validation
stage.
For more information about Burning Rock, please visit:
www.brbiotech.com.
Enquiries:Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Sep 2023 to Sep 2024